Company Update. March 2012

(1)

March 2012

(2)

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements

due to various risk factors and uncertainties including changes in business, economic

competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the

availability of financing.

These and other risks and uncertainties are detailed in the Company’s Annual Report.

(3)

Business Strategy

Page 3

Technology

Powerful proprietary

technology platform drives

partnered programs…

and increasingly, proprietary

product development

Strong current cash-flow plus substantial

upside through milestones & royalties

Lucrative upside

Partnerships

(4)

Maturing Pipeline Illustrates Successful

Execution of Strategy

8

17

20

4

11

12

11

4

6

8

9

0

5

10

15

20

25 2009

2010

2011

as of today

Total

Phase 1

Phase 2

Programs



20 clinical programs ongoing



16 with seven different partners



4 proprietary, un-partnered programs



Disease areas include cancer,

inflammation, CNS, ophthalmology,

musculoskeletal, and others

(5)

Strong Track Record of Technological

Innovation

HuCAL

30 commercial

partnerships

>€450 million

revenues to date

Most successful

antibody library

technology

Slonomics

Generation of

customized protein

libraries

4 deals since

acquisition

Optimization of any

therapeutic or

diagnostic antibody

arYla

Ylanthia

Next-generation

antibody library

extends technology

leadership

2012

2010

2001

Page 5

(6)

Slonomics:

Multiple Opportunities Beyond Antibodies

Research

&

Dx

Industrial

Enzymes

Slonomics

Rx

Proteins



e.g. Pfizer deal

(2010)



Second deal

(2012)



e.g. Novozymes

deal (2011)



e.g. Dana-Farber

alliance (2011)

(7)

76 Therapeutic Antibody Programs Ongoing,

20 in Clinical Trials

Page 7

Program Partner Indication Discovery Pre-clinic Phase 1 Phase 2

MOR103 (2 programs) - Rheumatoid arthritis, Multiple sclerosis CNTO888 (2 programs) Janssen Biotech/J&J Cancer,

Idiopathic pulmonary fibrosis CNTO1959 Janssen Biotech/J&J Psoriasis

BHQ880 Novartis Cancer

BYM338 Novartis Musculoskeletal

NOV – 3 Novartis not discl.

NOV – 4 Novartis Ophthalmology

Gantenerumab Roche Alzheimer’s Disease

MOR208 - Cancer

MOR202 - Cancer

BAY94-9343 (ADC) Bayer HealthCare Cancer BI – 1 Boehringer Ingelheim not discl. CNTO3157 Janssen Biotech/J&J Asthma CNTO – 5 Janssen Biotech/J&J Inflammation

NOV – 5 Novartis Inflammation

OMP-18R5 Oncomed Cancer

OMP-59R5 Oncomed Cancer

PFE – 1 Pfizer Cancer

24 Partnered Programs Various Partners Various Indications 32 Programs, incl.

2 co-dev with Novartis Various Partners Various Indications

68 Partnered Programs

8 Proprietary Programs

New

New in 2011/2012

New New New New New New

(8)

Current Pipeline

Projected HuCAL Drugs on the Market

Discovery

Preclinic

Phase 1

Phase 2

Phase 3

Market

Projection from today’s pipeline:

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

50%

70%

40%

65%

Projected number of marketed HuCAL drugs from today’s pipeline: 14

4

32 Success probability of 11%

4

24 Success probability of 18%

3

11 Success probability of 25%

9 Success probability of 33%

3

(9)

MOR103

New Mode of Action in Inflammation

The Drug



Ultra-high affinity HuCAL IgG1 targeting GM-CSF

Market



Large commercial potential in inflammatory

conditions including RA, MS, & others



Revenues with approved biologics in RA in 2010

exceeded USD15bn

Intellectual Property



Exclusive license to a US patent covering

anti-GM-CSF antibodies for the treatment of chronic

inflammatory conditions



US patent on MOR103 composition of matter

Development



European phase 1b/2a trial in RA fully recruited,

data expected Q3 2012



Ph1b safety study in MS patients initiated in Q4/11



PK study for sc administration initiated in Q1/12

Page 9

Proportion of subjects achieving a change of 1.2 from

baseline in DAS28-CRP

Source: ACR2011 Abstract: Mavrilimumab (an Anti-GM-CSFRα Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study

http://acr.confex.com/acr/2011/webprogram/Paper24567.html

Phase 2 data for mavrilimumab, vs. GM-CSF

receptor, provides clinical validation of the

(10)

GM-CSF is a Key Target in the

Pathophysiology of Inflammatory Diseases

Adapted from:

(11)

MOR103

European Phase 1b/2a Trial in RA

Trial

A Study of the safety and preliminary efficacy of MOR103, a human antibody to

granulocyte macrophage colony-stimulating factor (GM-CSF)

Patients

Patients with active rheumatoid arthritis

Study Design

Randomized, double-blind, placebo-controlled, multi-center dose-escalation

study (three groups with 0.3/1.0/1.5 mg/kg) of MOR103 on background of stable

regimen of concomitant RA therapy (NSAIDs, steroids, non- biological

DMARDs)

Primary Endpoint

Adverse event rate and safety profile

Secondary Endpoints

DAS28, ACR core set measures and EULAR28 response criteria, hematology,

blood chemistry, Ig levels, cytokines, synovitis, bone edema

Study Details



96 patients



Sites in Germany, The Netherlands, Bulgaria, Poland, Ukraine



Inclusion of MRI to detect an effect on inflammatory changes such as

synovitis or bone edema



Results in Q3 2012

(12)

MOR103

European Phase 1b Trial in MS

Trial

Phase Ib study to evaluate the safety and pharmacokinetics of MOR103, a

human antibody to GM-CSF, in patients with multiple sclerosis (MS)

Patients

Patients with relapsing-remitting or secondary progressive MS (RRMS or

SPMS)

Study Design

A randomized, double-blind, placebo-controlled study (three groups with

0.5/1.0/2.0 mg/kg; 6 doses) to evaluate the safety and pharmacokinetics of

MOR103, a human antibody to GM-CSF, in patients with multiple sclerosis

Primary Endpoint

Incidence and severity of adverse events

Secondary Endpoints



Pharmacokinetic profile



Potential immunogenicity

Study Details



30 patients



Sites in Germany, Poland, UK

(13)

MOR208 (XmAb5574) – A Novel

High-Potential Anti-Cancer Antibody

The Drug



Humanized, high affinity anti-CD19 antibody,

exclusive license from Xencor



Comprises a proprietary Xencor modification

leading to rapid and sustained B-cell depletion

Market



High unmet medical need in NHL, CLL & ALL

Competitive Profile



Expect convenient dosing schedule



Straightforward manufacturing



Potential for good safety profile



Significantly increased ADCC compared to

rituximab

in vitro

Development



Completion of phase 1 in CLL and reporting of

interim data H2/12



Initiation of additional trials in B cell

malignancies in 2012

(14)

MOR208 (XmAb5574)

Phase 1 Trial in the US

Trial

Safety and tolerability of MOR208 (XmAb5574) in Chronic Lymphocytic Leukemia

Patients

Patients with relapsed or refractory CLL/SLL

Study Design



MOR208/XmAb5574 (humanized, Fc-engineered, anti-CD19 IgG1 antibody)



Open-label, multi-dose, single-arm, Phase 1, dose-escalation study

Primary Endpoint

To determine the dose limiting toxicities (time frame 28 days)

Study Details



30 patients



Identification of the maximum tolerated dose (MTD) and/or recommended

dose(s) (RD) for further study



Characterization of safety and tolerability, PK, PD and immunogenicity



Evaluation of preliminary antitumor activity of XmAb5574 in patients with

relapsed or refractory CLL/SLL

(15)

MOR202 – A Novel High-Potential Antibody

for Multiple Myeloma

The Drug



High affinity HuCAL antibody targeting CD38

The Market



High unmet medical need in MM, accounting for

approximately 1% of all cancers.



Median survival is approximately 3-5 years

Competitive Profile



Use of targeted therapy in combination with standard

regimens in myeloma can minimize adverse events

while increasing efficacy



MOR202 monotherapy shows a dose-dependent

reduction of multiple myeloma graft induced bone

lysis (pre-clinical studies)



MOR202 plus bortezomib or lenalidomide

synergistically inhibits bone lysis and substantially

reduces M protein levels

(pre-clinical studies)

Development



Study to last until January 2015, interim reporting

planned

Page 15 Non-inoculate d Vehicle MOR202 3mg/kg0.6mg/kg BOR MOR202+BOR (3+0. 6mg/kg) 0 10 20 30 40 50 60 70 80 90 100 110 % ly sis of v e hicle control

M

OR

202 /

B

OR

Bone lysis

Non -ino culate d Vehic le MOR202 3mg/kgLEN 50mg/kg MOR202+LEN (3+50mg/kg) 0 10 20 30 40 50 60 70 80 90 100 110 % ly sis of v e hic le co ntro l

M

OR

202 /

L

EN

Vehic le MOR2 02 3 mg/ kg BOR 0.6mg/ kg MO R202 +BOR (3+0 .6mg/ kg) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 n o rm a li s e d M p ro te in l e v e l Vehic le MO R202 3m g/kg LEN 50mg/k g MOR2 02+LEN (3+50mg/k g) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 n o rm a li s e d M p ro te in l e v e l

M protein

MOR202/BOR and MOR202/LEN combination

therapy is superior to the respective mono therapies

(16)

MOR202

European Phase 1/2a Trial

Trial

A phase I/IIa, open-label, multicentre, dose-escalation study to evaluate the safety

and preliminary efficacy of the human anti-CD38 antibody MOR202 as monotherapy

and in combination with standard therapy in subjects with relapsed/refractory multiple

myeloma

Patients

Patients relapsed/refractory multiple myeloma; failure of at least 2 prior therapies

Study Design

• MOR202 (anti-CD38 HuCAL IgG1 antibody)

• Phase I dose escalation (iv administration of MOR202 for up to 2 cycles)

• Phase IIa monotherapy extension (iv administration of MOR202 for up to 4 cycles)

• Phase Ib MOR202 combined with bortezomib

• Phase Ib MOR202 combined with lenalidomide

Primary

Endpoint

• Determination of MTD and / or recommended dose (up to 20 weeks)

• Safety & immunogenicity

Secondary

Endpoints

• Pharmacokinetics of MOR202

• Overall response rate (standard response criteria, serum M protein levels)

(17)

AbD Serotec Segment Complements

Therapeutic Business

Page 17

Research Activities



Catalogue of 15,000+ products



Stable and recurring cash flows



Customers comprise universities,

government bodies, life science

companies



Website, eCommerce

HuCAL – Diagnostic Applications



Custom antibody generation



Using proprietary technologies to

deliver superior Dx antibodies



Future upside via royalties



Collaborations with more than 20

diagnostics companies

(18)

FY2011: Income Statement

in € million

2011

2010

Change

Revenues

100.8

87.0 +16%

Cost of Goods Sold

7.0

7.3 Total Research and Development Expenses

57.5

46.9 Sales, General & Administrative Expenses

24.6

23.2 Total Operating Expenses

89.1

77.4 +15%

Other Operating Income

0.5

0.2 Profit from Operations

12.2

9.8 +24%

Finance Income

1.4

4.1 Other Expenses

2.1

0.8 Profit before Taxes

11.4

13.2 -14%

Income Tax Expenses

3.2

4.0 Net Profit

8.2

9.2 -11%

(19)

Institutional

Investors

46%

Retail Investors

22%

Unidentified

23%

Treasury Stock

0.7%

Management &

Supervisory Boards

1.9%

Novartis

6.4%

Balance Sheet and Shareholder Structure

Page 19

Shareholdings by Investor Type (12/2011)

Shares issued: 23,112,167 (Dec. 31, 2011)

Balance Sheet

EUR millions

Dec. 31,

2011

Dec. 31,

2010

Assets

Cash, Cash Equivalents &

Marketable Securities

134.4

108.4 Other Current Assets

20.3

24.1 Total Non-Current Assets

73.7

77.3 Total Assets

228.4

209.8 Liabilities

Total Current Liabilities

23.8

21.4 Total Non-Current Liabilities

7.5

2.5 Total Shareholders’ Equity

197.1

185.9

(20)

Guidance 2012

in € million

2012

2011

Group Revenues

75 – 80

100.8 Investment into Proprietary R&D

20 – 25

36.7 Group EBIT

1 – 5

11.1 in € million

2012

2011

AbD Serotec Segment Revenues

(at constant currency)

20 – 22

19.3 AbD Serotec EBIT Margin

(21)

Enrollment target

nearly hit in phase 1

trial

Data in H2 2012

MOR208

Proprietary Clinical Programs to Advance

Significantly in 2012

MOR202

Phase 1/2a trial

initiated in Q3 2011

Combination arms to

start in 2013

MM

CLL

MOR103

Enrollment completed

in phase 1b/2a trial in

rheumatoid arthritis

Data in Q3 2012

MOR103

Phase 1b trial in

multiple sclerosis

initiated in Q4 2011

Data in 2013

MS

RA

SC

Page 21

(22)

A Wealth of Clinical Data is Imminent

H2 2011

H1 2012

H2 2012

H1 2013

NOV – 2 (Ophthalmology)

CNTO – 1 (Inflammation)

CNTO888 (Cancer)

BYM338 (Musculoskeletal)

CNTO3157 (Asthma)

MOR208 (CLL)

BHQ880 (Cancer)

CNTO888 (IPF)

OMP18-R5 (Cancer)

OMP59-R5 (Cancer)

MOR103 (RA)

BYM338 (Musculoskeletal)

NOV – 3 (n.d.)

NOV – 4 (Ophthalmology)

PFE – 1 (Cancer)

CNTO1959 (Psoriasis)

BI – 1 (n.d.)

BHQ880 (Cancer)

NOV – 4 (Ophthalmology)

NOV – 3 (n.d.)

light colors: phase 1

dark colors: phase 2

(23)

(24)

Novartis Alliance: Landmark Deal

Timeline



May 2004: Initial deal, including equity stake



November 2007: Major expansion



November 2017: End, subject to 2-year extension option

Novartis pays…



Approx. €20m p.a. technology license including HuCAL internalization fees



Approx. €20m p.a. in research funding



Over €250m milestones (probability adjusted)



Royalties on all resulting drugs

Novartis gets…



Preferred access to HuCAL for use in over 100 discovery programs

Co-development

option



Shared costs & profits (20% – 50%) on selected co-developed programs

Excluded



Most infectious disease targets

(25)

Partnerships: Typical Terms per Program

Page 25

Discovery

Preclinic

Phase 1

Phase 2

Phase 3

Market

Phase 1 milestone

Phase 3 milestone

Biologics

License

Application

+

Approval

milestones

Royalties

(mid single

digits)

Exclusive license fee; R&D funding

MorphoSys costs

(26)

Partnered Programs

Phase 2 Clinical Development

Program

Partner

Disease

Target

Status

CNTO888

Janssen

Biotech

Oncology

CCL2

(MCP-1)

Two trials ongoing, one trial completed

CNTO888

Janssen

Biotech

Idiopathic

pulmonary

fibrosis

CCL2

(MCP-1)

Novel approach to IPF

CNTO1959

Janssen

Biotech

Psoriasis

IL23p19

Phase 2 trial started in December 2011

n.d.

Novartis

n.d.

Clinical proof of concept achieved

n.d.

Novartis

Ophthalmology

n.d.

Phase 2 trial started in January 2012

BHQ880

Novartis

Osteolytic bone

disease

DKK-1

Early data show stimulation of bone

formation

BYM338

Novartis

Musculoskeletal n.d.

Two phase 2 trials ongoing

Gantenerumab Roche

Alzheimer‘s

disease

Amyloid-

b

Only anti-Aβ antibody being developed

in patients with prodromal AD

(27)

Partnered Programs

Phase 1 Clinical Development

Program

Partner

Disease

Phase 1 Start

BAY94-9343

Bayer

Oncology

September 2011

n.d.

Boehringer Ingelheim

n.d.

December 2010

CNTO3157

Janssen Biotech

Asthma

June 2010

n.d.

Janssen Biotech

Inflammation / Autoimmune

December 2010

n.d.

Novartis

Inflammation

December 2010

OMP-18R5

Oncomed

Oncology

April 2011

OMP-59R5

Oncomed

Oncology

December 2010

n.d.

Pfizer

Oncology

December 2010

(28)

Carlumab (CNTO 888): CCL2 Specific

Antibody in Oncology

A Study of the Safety and Efficacy of CNTO 888 in Combination With Standard of Care Chemotherapy in Patients With Solid Tumors

Status Phase 1 (completed)

Study Design Non-randomized, open-label safety study Study Start Date May 2010

Completion Date n.d. Enrollment 53

Primary Outcome Measures

The primary objective of the study is to evaluate the safety of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care

chemotherapy regimens (docetaxel; gemcitabine; Paclitaxel and carboplatin; or DOXIL®/ Caelyx® doxorubicin HCl liposome injection)

Secondary Outcome Measures

Pharmacokinetics [during study as specified in the protocol and at End of Study (1 year)] Pharmacodynamics [during study as specified

in the protocol and at End of Study (1 year)]

Treatment Period

Combination therapy will be continued until disease progression, unacceptable toxicity, the patient refuses further combination therapy, withdraws consent, or is treated for 1 year

A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer

Status Phase 2 (completed)

Study Design Non-randomized, open-label safety/efficacy study Study Start Date September 2009

Completion Date July 2011 Enrollment 46

The primary objective of the study is to determine the composite response in patients with

metastatic castrate-resistant prostate cancer (CRPC) who receive single-agent 15 mg/kg CNTO 888 every 2 weeks (Time Frame: 3-6 months)

Objective response rate determined as complete response and partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines

Progression Free Survival Overall Survival

Treatment Period

15mg/kg intravenously every 2 weeks until disease progression

(29)

Carlumab (CNTO 888): CCL2 Specific

Antibody in Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status Phase 2 (active, not recruiting)

Study Design Randomized, double-blinded safety/efficacy study Study Start Date December 2008

Completion Date June 2012

Enrollment 129

Primary Outcome Measures The primary objective is to determine the efficacy (as measured by pulmonary function) and safety of CNTO 888 in subjects with IPF.

To assess the effect of CNTO888 on measures of disease progression, patient reported outcomes, functional capacity and health-related quality of life, and to assess the pharmacokinetics/ pharmaco-dynamics of CNTO888 in subjects with IPF.

Treatment Period

Patients will receive study agent until Week 48 and will continue to be followed through Week 72 for assessment of safety and any other effects after discontinuation of therapy.

Patients will be in the study for about 74 weeks. Group 1: placebo

Group 2: 1 g/kg CNTO888 every 4 weeks Group 3: 5mg/kg CNTO888 every 4 weeks Group 4: 15 mg/kg CNTO888 every 4 weeks

(30)

CNTO1959: HuCAL Antibody for the

Treatment of Patients with Psoriasis

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE) Status Phase 2 (recruiting)

Study Design Randomized, double-blind, placebo-controlled study

Study Start Date October 2011 Completion Date February 2014 Enrollment 280

Physician's Global Assessment (PGA) score of cleared or minimal (Time Frame: Week 16); Overall assessment of induration, scaling, and erythema

Psoriasis Area and Severity Index (PASI) 75% or greater improvement from baseline

(Time Frame: Week 16)

The difference in the PGA score of cleared (0) or minimal (1) response rate between CNTO 1959 treatment groups and adalimumab treat-ment group (Time Frame: Weeks 16 and 40) The change from baseline in Dermatology Life

Quality Index (DLQI) (Time Frame: Week 16)

Treatment

5 groups: CNTO 1959 (5 mg / 15 mg / 50 mg / 100 mg / 200 mg

Drug: Adalimumab

Drug: Placebo to CNTO 1959 (100 mg)

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single SC Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Status Phase 1 (recruiting)

Study Start Date August 2011 Completion Date June 2013 Enrollment 32

The number and type of adverse events Change in clinical laboratory values Electrocardiogram

Changes or abnormalities in body systems Axillary temperature

Pulse rate

Blood pressure (Time Frame: Up to 24 weeks) Secondary

Outcome Measures

Blood levels of CNTO 1959 Antibodies to CNTO 1959

Psoriasis Area and Severity Index (PASI) Physician's Global Assessment (PGA)

Treatment

Drug: CNTO 1959 (10mg, 30mg, 100mg, 300mg, subcutaneous use, ascending dosing for 24 weeks

(31)

BHQ880: DKK-1 Specific Antibody in

Multiple Myeloma Associated Osteolysis

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Status Phase 1/2 (active, not recruiting)

Study Design Randomized, double-blinded safety/efficacy study Study Start Date January 2009

Completion Date April 2012

Enrollment 267

Time to first SRE and change in bone markers for bone resorption and formation (Time Frame: 9 months minimum treatment with BHQ880 or placebo in combination with zoledronic acid and standard anti-myeloma therapy

Characterize acute and chronic safety and tolerability of BHQ880

Characterize single-dose and repeated-dose pharmacokinetic profiles of BHQ880 Assess the potential immunogenicity of BHQ880

Characterize the binding kinetics of DKK1/BHQ880 complex (free&BHQ880 bound DKK1) in serum Determine the pharmacodynamic effects of BHQ880 by measuring biochemical markers of bone

formation, resorption, and metabolism in serum and urine

Treatment Period

Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid Group 1: Various intravenous doses (low) of BHQ880 (up to 20 mg/kg) in combination with

zoledronic acid on day 1 of a 28-day cycle.

Goup 2: Various intravenous doses (medium) of BHQ880 (up to 20 mg/kg) in combination with zoledronic acid on day 1 of a 28-day cycle.

Group 3: Various intravenous doses (high) of BHQ880 (up to 20 mg/kg) in combination with zoledronic acid on day 1 of a 28-day cycle.

Group 4: Placebo in combination with zoledronic acid on day 1 of a 28-day cycle

(32)

BHQ880: DKK-1 Specific Antibody in

Multiple Myeloma Associated Osteolysis

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Study Design Non-randomized, open-label study Study Start Date May 2011

Completion Date March 2013

Enrollment 40

Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A (Time frame: at 6 months)

Safety and tolerability of BHQ880 in patients with smoldering multiple myeloma by assessing AEs, SAEs, clinical laboratory values (Time frame: From start of study until disease progression ) Characterize the PK profile of BHQ880 as a single agent administered monthly by assessing

BHQ880 levels in plasma (Time frame: Throughout the study until disease progression) Evaluate the effect of BHQ880 on bone metabolism by assessing serum and urine bone

biomarkers (Time frame: Throughout the study until disease progression)

Evaluate the effect of BHQ880 on bone mineral density by DXA scan and QCT (Time frame: 6 months and 12 months)

Treatment Period

This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma

BHQ880 will be administered every 28 days in previously untreated patients. Single arm

(33)

BHQ880: DKK-1 Specific Antibody in

Multiple Myeloma Associated Osteolysis

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Study Design Randomized, double-blinded study Study Start Date May 2011

Completion Date February 2016

Enrollment 144

Effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone (Time Frame: 18-month median time to first SRE assumed for the placebo arm)

Safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib (Determine the

pharmacokinetic parameters for BHQ880 and bortezomib. Evaluate the effect of BHQ880 on bone metabolism

1) Change in bone mineral density, measured by dual-emission X-ray absorptiometry (DXA), 2) Change in bone strength, measured by quantitative computed tomography (qCT),

Determine the anti-myeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone

1) The overall response rate (partial response plus complete response); 2) Progression-free survival following initiation of BHQ880

Treatment Period

The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.

(34)

BYM338: HuCAL Antibody for the

Unintentional Weight Loss in Cancer Patients

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Study Start Date August 2011 Completion Date December 2011 Enrollment 12

Assessment of the affect of BYM338 on thigh muscle volume by MRI (time frame: 8 weeks)

Assessment of the effect of BYM338 on muscle function by 'Timed Get Up and Go' test

(Time frame: 8 weeks)

Patients Patients with sporadic Inclusion Body Myositis

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Study Start Date August 2011 Completion Date September 2012 Enrollment 50

Increase in thigh muscle volume as measured by MRI (Time Frame: 8 Weeks)

6 minute walk test (Time frame: 8 weeks) Efficacy in treating unintentional weight loss

(Time frame: 8 weeks)

Obtain pharmacokinetic data in this population (Time frame: 8 weeks)

Efficacy in improving total lean body mass (LBM) and total bone mineral content (Time frame: 8 weeks)

Improving physical activity and function (Time frame: 8 weeks)

Patients

Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas

(35)

Gantenerumab: Amyloid-ß Specific Antibody

in Alzheimer‘s Disease

A Study of Gantenerumab (RG1450) in Patients With Prodromal Alzheimer's Disease

Study Design Randomized, double-blinded safety/efficacy study Study Start Date November 2010

Completion Date April 2015

Enrollment 360

To evaluate the effect on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability

Sub-study: Change in brain amyloid over time assessed with Positron Emission Tomography

Effect on cognition assessed with Alzheimer Disease Assessment Scale-Cognition Effect on functioning assessed with Functional Activities Questionnaire

Safety (nature and incidence of adverse events) Pharmacokinetics: gantenerumab levels

Treatment Period

Patients will be randomized to receive subcutaneous injections of either gantenerumab or placebo Patients who consent to be part of the sub-study will undergo positron emission tomography (PET)

scanning to assess brain amyloid

The anticipated time on study treatment is 104 weeks.

Group 1: 225 mg gantenerumab subcutaneous doses every 4 weeks for 104 weeks Group 2: 105 mg gantenerumab subcutaneous doses every 4 weeks for 104 weeks Group 3: Placebo

Clinical Data

In October 2011, Roche published first amyloid imaging data from Gantenerumab

The data, published in the Archives of Neurology, demonstrated a dose-dependent reduction of beta amyloid in the brain of patients treated with the monoclonal antibody, while amyloid load increased in patients on placebo

(36)

Management Team

Dr. Simon E. Moroney, CEO



Co-founder, previously at ImmunoGen



German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding

Services to the Bavarian Economy (2009)

Jens Holstein, CFO



Joined MorphoSys in 2011



Formerly at Fresenius: Regional CFO for region EME of Fresenius Kabi AG; several

financial and general management positions at Fresenius; and in consulting industry

Dr. Arndt Schottelius, CDO



Joined MorphoSys in 2008



Formerly Medical Director in Immunology at Genentech Inc.; Berlex Biosciences, USA;

Schering, Germany; Charité University Hospital, Berlin

Dr. Marlies Sproll, CSO



Joined MorphoSys in 2000, promoted to CSO in 2005

(37)

Covering Analysts

Institution

Contact

Close Brother Seydler

Mr. Igor Kim

Commerzbank

Mr. Daniel Wendorff

Deutsche Bank

Mr. Gunnar Romer

DZ Bank

Dr. Elmar Kraus

Edison

Dr. Mick Cooper

Equinet Institutional Services

Edouard Aubéry

Helvea

Dr. Olav Zilian

Kempen & Co.

Mr. Sachin Soni / Mr. Mark Pospisilik

Landesbank Baden-Württemberg

Mr. Timo Kürschner

Nomura Code

Dr. Gary Waanders

WestLB AG

Dr. Cornelia Thomas / Mr. Oliver Kaemmerer

(38)

Upcoming Events & Conferences



March 22, 2012

Kempen Healthcare/Life Sciences Conference

Amsterdam, The Netherlands



May 4, 2012

Q1 2012 Results



May 7-9, 2012

Deutsche Bank Health Care Conference

Boston, USA



May 14-16, 2012

German Swiss & Austrian Conference 2012

Frankfurt, Germany



May 15-16, 2012

BioEquity, Frankfurt, Germany



June 4-7, 2012

Jefferies 2012 Global Healthcare Conference

New York, USA

(39)

(40)

www.morphosys.com

Thank You

HuCAL®_{, HuCAL GOLD}®_{, HuCAL PLATINUM}®_{, Ylanthia}®_{, arYla}®_{, CysDisplay}®_{, RapMAT}®_{and AutoCAL}®_{are registered trademarks of MorphoSys AG.}